IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
By Tom Wilbur | November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...
Read More
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
By Katie Koziara | November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....
Read More
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
By Tom Wilbur | October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.
Read More
Pelosi’s radical plan leaves lung cancer patients behind
By Tom Wilbur | October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...
Read More
Guest post: Sharing discounts and rebates is the right thing to do
By Guest Contributor | October 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
PhRMA CEO in STAT: Pelosi’s drug pricing plan puts medical innovation at risk
By Holly Campbell | October 17, 2019
The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published in STAT First Opinion here on October 17, 2019. The future of medical innovation in America is at a...
Read More
Pelosi’s radical plan would leave Alzheimer’s patients behind
By Tom Wilbur | October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation
By Andrew Powaleny | October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...
Read More
Pelosi’s radical plan would leave ALS patients behind
By Tom Wilbur | October 15, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...
Read More
Remembering Harrison Cook, Vice President for International Government Affairs at Eli Lilly and Company
By Guest Contributor | October 11, 2019
Guest authors of this blog are:
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
